Ardsley Advisory Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ardsley Advisory Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-60,000	Closed	-$4.79M	–	164
2022 Q2	$4.79M	Sell	60,000 -25,000	-29%	-$2.37M	0.79%	34
2022 Q1	$8.94M	Sell	85,000 -55,000	-39%	-$5.36M	1.49%	20
2021 Q4	$15.1M	Sell	140,000 -136,000	-49%	-$14.8M	2.88%	8
2021 Q3	$30.2M	Sell	276,000 -9,000	-3%	-$934K	4.61%	5
2021 Q2	$26.7M	Buy	285,000 +35,000	+14%	+$3.22M	3.14%	6
2021 Q1	$23M	Buy	250,000 +50,000	+25%	+$4.22M	2.8%	10
2020 Q4	$14.6M	Buy	200,000 +65,000	+48%	+$4.83M	2.4%	12
2020 Q3	$10.5M	Buy	+135,000	New	+$9.29M	2.02%	17
2017 Q3	–	Sell	-40,000	Closed	-$475K	–	177
2017 Q2	$475K	Buy	40,000 +16,500	+70%	+$205K	0.07%	96
2017 Q1	$347K	Buy	+23,500	New	+$381K	0.05%	115
2015 Q1	–	Sell	-15,000	Closed	-$193K	–	261
2014 Q4	$193K	Buy	+15,000	New	+$188K	0.03%	167

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ardsley Advisory Partners's HZNP Position: Q3 2022 in Review

Ardsley Advisory Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 60,000 shares — an estimated $4.79M sold.

Ardsley Advisory Partners first reported a position in HZNP in Q4 2014 and held it in 11 quarters. The position peaked at $30.2M in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Ardsley Advisory Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Ardsley Advisory Partners sold 60,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $4.79M.
Ardsley Advisory Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 11 quarters.
Ardsley Advisory Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.2M in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Ardsley Advisory Partners's 13F filing for Q3 2022, filed 14 Nov 2022.